CYAD - Dosing underway in Celyad Oncology's early-stage CYAD-211 study for multiple myeloma

The first patient has been dosed in Celyad Oncology's (CYAD) Phase 1 IMMUNICY-1 trial of CYAD-211, a novel, short hairpin RNA (shRNA)-based anti-B-cell maturation antigen candidate for the treatment of relapsed/refractory multiple myeloma (r/r MM).The trial will evaluate multiple dose levels of CYAD-211: 3x107, 1x108 and 3x108 cells per infusion. "Enrollment in the IMMUNICY-1 trial will continue over the coming months and we expect to report proof-of-concept data from the initial dose cohorts of the trial during the first half of 2021,” said Frédéric Lehmann, VP of Clinical Development & Medical Affairs. The Company received €3.4M in non-dilutive funding from the SPW-Recherche of the Walloon Region, which will support the development of CYAD 211.

For further details see:

Dosing underway in Celyad Oncology's early-stage CYAD-211 study for multiple myeloma